Drug Discovery Informatics Market Outlook 2031
The global drug discovery informatics market size was USD 2.96 Billion in 2022 and is projected to reach USD 7.76 Billion by 2031 expand at a CAGR of 11.3% during the forecast period, 2023–2031. The growth of the market is attributed to the rising number of high-performance computers and online services. Moreover, increasing acceptance of in-silico modelling tools, expanding volume of drug discovery data, and rising requirement for innovative pharmaceutical moieties are driving the market growth.
Drug discovery informatics software can identify potential drug candidates for the development of new drug entities by analyzing and interpreting a large pool of clinical data and information. Medical professionals generate massive amount of data when conducting research into specific diseases or patient demographics. The goal of discovery informatics is to develop systems that can work efficiently with such large sets of clinical trial and treatment data.
The informatics platform allows users to organize peptide sequences by color code and property. Thus, the rise in the preference for molecular modelling is due to the increasing application of the platform in the drug discovery process. The tools that are used in the modelling and simulation of biological systems and small molecules help in understanding and predicting the behavior at the molecular level. Furthermore, they improve the cost-efficiency of hit discovery and hit-to-lead optimization.
Drug Discovery Informatics Market Trends, Drivers, Restraints, and Opportunities
- Increasing investment in the Covid-19 drug discovery throughout the world is anticipated to boost the market expansion during the forecast period. To provide quick solutions, scientists are conducting virtual screening of drugs to target viral proteins and human ACE2 receptors. These studies use in-silico tools to screen small molecules with the potential to be used in drug discovery against Covid-19.
- Rapid development of web services & solutions by major industry players to assist in various stages of Covid-19 drug development is one of the major factors boosting the market growth.
- The introduction of improved drug discovery information technology is anticipated to create lucrative opportunities for the market players in the projected timeline. For instance, Certara, Inc., released an updated version of its Simcyp physiologically-based pharmacokinetic (PBPK) simulator platform in January 2021. The new models may be used to evaluate and analyze medication activity throughout pregnancy and breastfeeding.
Scope of Drug Discovery Informatics Market Report
The report on the global drug discovery informatics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Drug Discovery Informatics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Modes (In-house and Outsourced), Workflow (Discovery Informatics [Identification, Validation, & Assay Development Informatics and Lead Generation] and Development Informatics [Lead Optimization, FHD Preparation, Phase IA, and Phase IB/2]), Services (Sequence Analysis Platforms, Docking, Molecular Modeling, Clinical Trial Data Management, and Other Services)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Certara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., and Illumina, Inc.
Drug Discovery Informatics Market Segment Insights
Outsourced segment is projected to constitute a major market share
On the basis of modes, the drug discovery informatics market is bifurcated into in-house and Outsourced. The outsourced segment is expected to account for a key market share during the forecast period due to rising number of agreements between pharmaceutical firms and contract development and manufacturing organizations.
Contract research organizations (CROs) are involved in the preparation of reports on novel drug entities that are then submitted to the food & drug administration (FDA) by the sponsor or drug manufacture.
However, the in-house segment is anticipated to expand at a CAGR of 11.73% during the forecast period owing to the increasing use of informatics for drug development by large-scale corporations due to its benefits, such as offering immediate access to information from a broad variety of sources, eliminating laborious data compilation and reformatting, and assisting in the combination of cross-disciplinary knowledge.
Discovery informatics segment is projected to represent a key market share
On the basis of workflows, the drug discovery informatics market is divided into discovery informatics and development informatics. The former segment is further divided into identification, validation, & assay development informatics and lead generation. Conversely, the latter segment is sub-segmented into lead optimization, FHD Preparation, phase IA, and phase IB/2.
The discovery informatics segment is expected to represent a significant market share in the coming years owing to a strong emphasis on the development of precision medicines. Precision medicine refers to administration of specific medicine that matches with patient's genetic and molecular profile. For instance, PerkinElmer, Inc. provides discovery informatics solutions for utilizing analytics for speedy drug discovery.
However, the development informatics segment is anticipated to expand at a rapid pace during the forecast period owing to the expanding number of drug candidates in the pipelines of pharmaceutical companies. These tools are used to conduct certain tasks in clinical trial design in order to improve overall trial performance.
Sequence analysis segment is anticipated to register a substantial CAGR
In terms of services, the market is divided into sequence analysis platforms, docking, molecular modeling, clinical trial data management, and other services. The sequence analysis segment is expected to exhibit a substantial CAGR during the forecast period. Bioinformatic solutions are widely used to create primary and secondary databases of nucleic acid, protein, and other biomolecule sequences.
Exploration and logistics of genome sequencing is done using informatics software to identify genes and targeted proteins, which assist in the development of potential drugs.
North America is expected to dominate the market
On the basis of regions, the drug discovery informatics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth is attributed to the presence of prominent players, high incidence of infectious diseases, and rapid adoption of new and advanced R&D tools.
Furthermore, businesses in the region are focusing on joint ventures and research collaborations, which is expected to drive the market growth in North America.
The global drug discovery informatics market has been segmented on the basis of
- Discovery Informatics
- Identification, Validation, & Assay Development Informatics
- Lead Generation
- Development Informatics
- Lead Optimization
- FHD Preparation
- Phase IA
- Phase IB/2
- Sequence Analysis Platforms
- Molecular Modeling
- Clinical Trial Data Management
- Other Services
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Boehringer Ingelheim International GmbH
- Infosys Ltd.
- Charles River Laboratories
- Collaborative Drug Discovery, Inc.
- Eurofins DiscoverX Products
- Jubilant Biosys
- Novo Informatics Pvt. Ltd.
- ChemAxon Ltd.
- Albany Molecular Research Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
Key players competing in the drug discovery informatics market are Certara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., and Illumina, Inc.
Companies are increasingly collaborating with other companies, research institutes, and CROs to enhance their market shares. In March 2020, Charles River Laboratories International, Inc. collaborated with Deciphex. The Patholytix Preclinical platform from Deciphex was expected to improve pathologists’ productivity and provide data to clients quickly.